 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12345678910111213...3839» |
- Biologic Drug and Anti-Drug Antibody Monitoring: All 5 TNF-Inhibitors, Infliximab, Adalimumab, Golimumab, Etanercept, Certolizumab Pegol, in 63,930 Patient Samples (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3180;
Though clinical histories and blood collection timing are not known, Figure 1 showed that many patients may have insufficient drug levels. Observed immunogenicity rates to IFX, ADL, CTZ and ETN were high and all anti-drug antibodies except anti-ETN adversely affect free drug levels.
- Elderly Patients (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3100;
Survival analysis showed that in our population high disease activity and history of adverse events are associated with the discontinuation of bDMARDs. V.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2898;
P4
V. In this investigator-initiated, randomized, open-label study (NCT01491815), patients with treatment-na
- Influence of Rheumatoid Factor on Serum Drug Levels of TNF Inhibitors with Different Structures in Rheumatoid Arthritis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2884;
These differences might aid physicians to select suitable treatment for the management of RA. Demographics characteristics of patients with RA treated with infliximab (IFX), adalimumab (ADL) and certolizumab (CTZ) at baseline.
- Cimzia (certolizumab pegol) / Astellas, UCB
Certolizumab Pegol Shows Longer Retention Rate in Comparison with Other TNF Inhibitors in Patients with Rheumatoid Arthritis and High Rheumatoid Factor Titers at Baseline. a Multicentre and Retrospective Study (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2876;
RF can bind the Fc fragment of infliximab, suggesting the hypothesis that it can also bind other monoclonal antibodies (mAB (Adalimumab, Golimumab and Infliximab)) and fusion proteins (FP (Etanercept)), leading to a lower drug levels and potential early withdrawal. High or very high RF titers before TNFi initiation were associated with a longer retention rate in non-na
- Cimzia (certolizumab pegol) / Astellas, UCB
Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2649;
P4
Table. Results of the final model after IPW N. Haroon: AbbVie, 2, Eli Lilly, 2, Janssen, 2, Novartis, 2, UCB Pharma, 2;
- Orencia (abatacept) / BMS, Actemra SC (tocilizumab SC) / Roche, Halozyme, Cimzia (certolizumab pegol) / Astellas, UCB
Obesity Is a Risk Factor for Poor Response to Treatment in Early Rheumatoid Arthritis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2524;
In patients with early RA, obesity was not associated with higher disease activity before treatment initiation. However, 24 weeks after treatment, patients with obesity had higher disease activity and lower chances to respond to therapy compared to patients with lower BMI irrespective of treatment.
- Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Targeting NET Formation in Early RA Patients; A Spin-off Study from the NORD-STAR (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2502;
All four treatments studied here reduced these detrimental processes within 3 months. The calprotectin reduction seen in this study is in line with an earlier spin-off study 2 .
- Humira (adalimumab) / AbbVie
Switching Patterns of Biological and Targeted Synthetic Therapies in Juvenile Idiopathic Arthritis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2493;
Our stratified analysis found that the JIA category defines the choice of ts/bDMARD and treatment sequences. This real-world data study can give useful information about treatment patterns and trend for switching in routine clinical practice.
- methotrexate / Generic mfg.
Breakthrough SARS-Cov-2 Infection and Disease Flares in Patients with Rheumatoid Arthritis: Result from COVAD E-Survey Study (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2359;
This real-world data study can give useful information about treatment patterns and trend for switching in routine clinical practice. Moreover, younger age (odds ratio, OR: 0.98, 95% CI: 0.96
- Comparisons of the Risk of Serious Infections Associated with the Different Classes of Targeted Therapies Used in Psoriatic Arthritis Patients: A Nationwide Cohort Study from the French Health Insurance Database (Room 33A-C; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_2074;
Compared with new users of adalimumab, this risk was lower among new users of etanercept and ustekinumab, with no difference among new users of the other TNF i , IL17 i or JAK i . Given the numerous therapeutic options available for PsA treatment, these findings could assist physicians in optimizing their therapeutic strategies based on individual patients' characteristics.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal, HEOR: Risk-sharing agreement based on health outcomes for the treatment of moderate-severe psoriasis with certolizumab pegol. (Pubmed Central) - Sep 23, 2023
Nearly 91% of patients reached the therapeutic target fixed in the RSA. Implementing this type of agreement can provide a direct or indirect benefit for all the agents involved in the process, providing valuable information for decision-making.
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date: CIMcare: A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO) (clinicaltrials.gov) - Sep 21, 2023
P3, N=150, Recruiting, Sponsor: UCB Biopharma SRL
Implementing this type of agreement can provide a direct or indirect benefit for all the agents involved in the process, providing valuable information for decision-making. Trial completion date: Dec 2026 --> Aug 2029
- Cimzia (certolizumab pegol) / Astellas, UCB
201: nr-axSpA: BREAKING THE CODE (Theater A) - Sep 15, 2023 - Abstract #ACRConvergence2023ACR_Convergence_348;
The session will then provide recommendations for MRI implementation and interpretation for nr-axSpA, leveraging a hypothetical patient case to complement the educational information. Lastly, the session will describe clinical trial outcomes in support of CIMZIA
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Cimzia (certolizumab pegol) / Astellas, UCB
Certolizumab Pegol Challenge for Treatment of Psoriasis in a Patient with Hypersensitivity Reaction to Infliximab (Monitor 01) - Sep 14, 2023 - Abstract #ACAAI2023ACAAI_553;
To prevent progression of psoriatic arthritis, with a history of a mild hypersensitivity reaction, it was reasonable to challenge with a separate TNF-alpha inhibitor. As certolizumab pegol is the only TNF-alpha inhibitor that is considered safe for pregnancy, a challenge was attempted and successful.
- |||| nipocalimab (M281) / J&J
New P2 trial, New P2a trial: DAISY: A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis (clinicaltrials.gov) - Sep 8, 2023
P2a, N=85, Recruiting, Sponsor: Janssen Research & Development, LLC
- | Cimzia (certolizumab pegol) / Astellas, UCB
Journal: Achievement of higher thresholds of clinical responses and lower levels of disease activity is associated with improvements in workplace and household productivity in patients with axial spondyloarthritis. (Pubmed Central) - Sep 7, 2023
P3
RAPID-axSpA (NCT01087762) was a 204-week phase III trial evaluating the safety and efficacy of certolizumab pegol (CZP) in adult patients with active axSpA...Over 4?years, achievement of higher clinical response thresholds and lower levels of disease activity was associated with fewer cumulative days affected by absenteeism or presenteeism, with clinical remission associated with the greatest improvements in productivity. This highlights the importance of targeting these thresholds to limit the burden of axSpA on society and on patients' daily lives.
- Therapeutics in immune-mediated diseases and fertility: what is the evidence of safety? (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_4415;
This highlights the importance of targeting these thresholds to limit the burden of axSpA on society and on patients' daily lives. The evidence are mostly dependent on low level evidence and will be demonstrated but it is certain that more studies and even case series need to be conducted in this area.
- Risk of Onset of Serious Infections in Psoriatic Patients Treated with either TNF-a, IL-17, or IL-23 Inhibitors: Results from a Retrospective Global Cohort (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2793;
Based on our results it might be necessary to include patient monitoring for infectious diseases under long-term therapy with biologics. However, further real-world data on the long-term safety of biologics are required.
- The risk of onset of malignancies and major cardiovascular diseases in psoriatic patients treated with either TNF-?, IL-23, or IL-17 inhibitors: results from a global retrospective study cohort. (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2791;
Our findings indicate that subsequent screenings for reported malignancies and MACEs should be included into daily clinical practice especially following treatment initiation with TNF-? inhibitors, as compared to treatment with IL-23 or IL-17 inhibitors.
- Sotyktu (deucravacitinib) / BMS
Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2760;
The median posterior estimate of PASI 75 response for deucravacitinib was 68% (95% credible interval [CrI], 52% ?82%) in the Asian population, which was higher than that for placebo (7%; 95% CrI, 6%-9%) and apremilast (26%; 95% CrI, 14%-43%). Deucravacitinib demonstrated robust efficacy in Asian populations, and it provides a convenient oral therapy option for patients with moderate to severe PsO, with efficacy similar to that of many biologic therapies.
- Is TNF-alpha inhibitor therapy a good choice for patients with concomitant hidradenitis suppurativa and psoriasis vulgaris? (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2751;
In cases where these two conditions coexist, the disease that appears first usually has a more severe clinical course and a worse therapeutic response, which is also the case with our patient. Given that the therapeutic response of our patient
- Bimzelx (bimekizumab) / UCB
Hidradenitis suppurativa, axial spondylarthritis, and pyoderma gangrenosum successfully treated with bimekizumab (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2279;
Its novel mechanism of action resulted in rapid and clinically meaningful improvements that translated into better outcomes for the patient. In our experience, bimekizumab was also effective for the treatment of pyoderma gangrenosum.
- | Trial completion, Checkpoint inhibition: TICIMEL: TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (clinicaltrials.gov) - Aug 14, 2023
P1, N=33, Completed, Sponsor: Institut Claudius Regaud
In our experience, bimekizumab was also effective for the treatment of pyoderma gangrenosum. Active, not recruiting --> Completed
- | Journal: Expenditure of biological drugs for rheumatoid arthritis treatment in the Brazilian public health system. (Pubmed Central) - Aug 13, 2023
Active, not recruiting --> Completed The results obtained allow us to draw a more recent profile of expenditure on RA treatment and indicate trends in the use of biological drugs for this condition, generating data that can support management decisions in public health policies.
- | Journal, Real-world evidence, Adherence, Real-world: Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Na (Pubmed Central) - Aug 11, 2023
Real-world data, showing differences in drug survival of bDMARDs and tsDMARD, can also be used in the variety of considerations when choosing treatment. Future studies could separate patients with RA into subgroups, which would also account for potential drug survival differences and enable personalized therapy.
- | Journal: Characteristic analysis of adverse reactions of five anti-TNF? agents: a descriptive analysis from WHO-VigiAccess. (Pubmed Central) - Aug 9, 2023
Current comparative observational studies of these inhibitors revealed common and specific adverse reactions in the ADR reports of the WHO received for these drugs. Clinicians should improve the rational use of these high-priced drugs according to the characteristics of ADRs.
- Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall, Cimzia (certolizumab pegol) / Astellas, UCB
(e-Poster Hall) - Aug 8, 2023 - Abstract #EADV2023EADV_1802;
blockers among other biologics are frequently prescribed. Considerations for changes in therapy during pregnancy have to regard specifics of medication and the vulnerable stages in pregnancy as well as the limited volume of recommended systemic therapeutics for psoriasis in pregnancy.
- Cimzia (certolizumab pegol) / Astellas, UCB
Real world data on the 1-year treatment of psoriasis with the use of certolizumab pegol in women of child-bearing potential (e-Poster Hall) - Aug 8, 2023 - Abstract #EADV2023EADV_1794;
P=N/A
The safety profile was consistent with that known for CZP. This suggests CZP offers a valuable option for disease control in WoCBP in a real-world clinical setting.
- Cimzia (certolizumab pegol) / Astellas, UCB
Real-world data on the use of certolizumab pegol for the treatment of moderate-to-severe plaque psoriasis: 1-year results from a prospective non-interventional cohort study (e-Poster Hall) - Aug 8, 2023 - Abstract #EADV2023EADV_1792;
P=N/A
Improved skin clearance and quality of life was observed in the overall cohort and across subgroups after CZP treatment. No new safety signal was identified for CZP.
- Dose escalation rates of biologics among patients with psoriasis in Germany: A retrospective analysis of InGef claims database (e-Poster Hall) - Aug 8, 2023 - Abstract #EADV2023EADV_1708;
RIS (an IL-23 inhibitor) was associated with the lowest rates of dose escalation. Dose escalation may be associated with unmet clinical goals and incremental economic burden to the German SHI.
- Humira (adalimumab) / AbbVie
Switching and discontinuation rates of biologics among psoriasis patients in Germany: A retrospective analysis of InGef claims database (e-Poster Hall) - Aug 8, 2023 - Abstract #EADV2023EADV_1695;
During the considered one-year period, treatment discontinuation occurred more often than treatment switching in patients with PsO initiating a biologic therapy. Rates of discontinuation and switching varied across agents and were lowest for RIS.
- Efficacy and safety of biological drugs in the treatmens of moderate-to-severe psoriasis in elderly patients (e-Poster Hall) - Aug 8, 2023 - Abstract #EADV2023EADV_1657;
The results of the present analysis are in line with those of clinical trials randomised clinical trials in the general population and with those of retrospective studies in the elderly population. The data obtained support the hypothesis of the effectiveness of biologic drugs even in patients over 65 and support the appropriateness of their use in clinical practice.
- EXTRAPULMONARY TUBERCULOSIS AND COVID-19 CO-INFECTION AS A COMPLICATION OF TNF-A INHIBITOR THERAPY (Convention Center Exhibit Hall - Rapid Area 2B) - Aug 4, 2023 - Abstract #CHEST2023CHEST_2981;
- || Review, Journal: Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments. (Pubmed Central) - Jul 31, 2023
In detail, conventional and biologic systemic drugs demonstrated efficacy in recent trials, including acitretin, methotrexate, cyclosporine, apremilast, adalimumab, infliximab, etanercept, certolizumab, golimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab and tildrakizumab. Several therapies have demonstrated efficacy and safety in the treatment of NP; however, the choice of treatment depends not only on the severity of the nail involvement, but also on whether PsA is present, the patient's comorbidities other than PsA, previous treatment history, and the patient's drug preferences.
- Neutropenic Enterocolitis in a Patient With a History of Crohn (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_4145;
She was recently diagnosed with acute myeloblastic leukemia (AML) and underwent Daunorubicin induction therapy, followed by Cytarabine consolidation therapy for two cycles, followed by an allogenic stem cell transplant...Filgrastim was added to her antimicrobial regimen...Detailed history, examination, laboratory and imaging findings are important to make the diagnosis. Figure: Figure 1- Thickening with trilaminar enhancement (yellow arrows) and engorgement of the vasa recta concerning for active inflammatory bowel disease.
- Mycobutin (rifabutin) / Pfizer, Lupin, Cimzia (certolizumab pegol) / Astellas, UCB
Successful Treatment of Pleural Tuberculosis While on Anti-Tumor Necrosis Factor Therapy for Crohn (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_4138;
Figure: Figure 1- Thickening with trilaminar enhancement (yellow arrows) and engorgement of the vasa recta concerning for active inflammatory bowel disease. Case Description/ A 26-year-old male healthcare worker with a history of longstanding Crohn
- Humira (adalimumab) / AbbVie
Rates of Extraintestinal Manifestations in Inflammatory Bowel Disease Patients on Gut Selective Compared to Non-Selective Biologic Therapy in the US (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_4064;
Analysis of EIM rates after biologic administration revealed statistically significant higher rates of primary sclerosing cholangitis (PSC) (1.13% vs 0.43%) (OR 2.65 CI 1.64-4.28) and Interstitial pneumonia (0.38% vs 0.13%) (OR 2.86 CI 1.23-6.63) in the VDZ group although both disorders were higher in this group prior to VDZ administration. However, other EIMs were at increased odds after VDZ despite being less present in this group prior to administration.
- Early Biologic Therapy in Inflammatory Bowel Disease Patients Is Associated With Improved Outcomes and Reduced Unplanned Care - A Nationwide Analysis (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_4063;
Out of which, 77,528 patients received a biologic within 2 years of diagnosis vs 24,530 patient first received a biologic after 2 years of diagnosis. Compared to the late biologic, early biologic IBD patients were significantly less likely to develop Clostridium Difficile infection (CDI) (OR 0.80 CI 0.76-0.84), total colectomy (OR 0.81 CI 0.78-0.84), pouchitis (OR 0.73 CI 0.67-0.80), deep venous thrombosis (DVT) (OR 0.71 CI 0.67-0.76) and Pulmonary embolism (PE) (OR 0.68 CI 0.62-0.75).
- Childhood Obesity Increases Risk of Adult-Onset IBD, but Adult-Onset Obesity May Lead to Worse Disease Outcomes (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_2665;
About 935,413 adults had IBD of which 671 had childhood obesity, 57,260 had adult-onset obesity, and 877,482 never had any obesity. Those in the C-OBESE group were significantly more likely to develop Crohn
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Tremfya (guselkumab) / J&J
Patient with Severe Refractory Crohn's Disease Achieved Remission on Golimumab with Guselkumab for Psoriasiform Rash and Delivered Healthy Term Infant (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1300;
Post-op certolizumab failed clinically, worsened psoriasis and was changed to adalimumab...She failed vedolizumab: she had worsened anemia and weight loss...She developed hypertension in the third trimester, managed with labetalol...It appears safe in conjunction with a second biologic as she has been receiving guselkumab for her psoriasis. She has also had a successful pregnancy on this therapy and delivered an AGA, healthy infant
- Enbrel (etanercept) / Pfizer, Amgen
Unveiling of Crohn's Colitis in a Patient With Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis Previously Treated With Etanercept and IL-17 Inhibitors (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1291;
inhibitors (etanercept) and IL-17 inhibitors (secukinumab and ixekizumab)...1 year prior to presentation, she was switched from etanercept to certolizumab pegol (Cimzia) and methotrexate (MTX)...She was switched from Cimzia to budesonide, infliximab, and oral MTX...Restage Colonoscopy showed a patchy erythematous mucosa in the cecum (b) and rectum (d). The examined portion of the terminal ileum (a) and hepatic flexure (c) was normal.
- Introspective Racial Disparity Assessment: Timing for Biologics Initiation Among Inflammatory Bowel Disease in a Safety Net Health System (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1186;
The examined portion of the terminal ileum (a) and hepatic flexure (c) was normal. All VW patients diagnosed with ulcerative colitis (UC) or Crohn
- Clinical Characteristics and Outcomes of Appendiceal Neoplasms in Inflammatory Bowel Disease: A Tertiary Care Center Experience (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1180;
A majority had UC (68.2%). Of these, four (13.3%) had backwash ileitis, 27 (90%) had extensive colitis, 12 (40%) had a history of colorectal neoplasia (most common location and type included right colon and low-grade dysplasia, respectively), and 6 (20%) had primary sclerosing cholangitis (PSC).
- Clinical Characteristics and Outcomes of Small Bowel Neoplasms in Crohn (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1179;
A majority had ileal CD (49.3%) with stricturing (49.3%) phenotype. Twelve (16.9%) had perianal disease and 3 (4.2%) had upper gastrointestinal (GI) involvement.
- Assessing the Risk of Pancreatic Diseases in Inflammatory Bowel Disease Patients on Biological Therapy: A Retrospective Cohort Study Using a Large Database (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1176;
Patients with CD or UC who were treated with biological therapy had a lower risk of chronic pancreatitis, exocrine pancreatic insufficiency, and pancreatic cancer compared to those who were not treated with biological therapy. However, CD patients treated with biological therapy had a higher risk of pancreatic cysts and pancreatic pseudocysts.
- Risk of Opportunistic Infections Among Inflammatory Bowel Disease Patients on Biologics: A Nationwide Database Study (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1175;
Patients on biologics had a higher risk of Legionella (OR 2.85, 95% CI 1.55-5.25, P 0.0004), Tuberculosis (OR 1.98, 95% CI 1.60-2.45, P < 0.0001), Clostridium difficile (OR 1.85, 95% CI 1.75-1.95, P < 0.0001), sepsis (OR 1.11, 95% CI 1.05-1.16, P < 0.0001), Histoplasmosis (OR 2.66, 95% CI 1.81-3.91, P < 0.0001), Candidiasis (OR 1.22, 95% CI 1.17-1.28, P < 0.0001), CMV (OR 1.21, 95% CI 1.05-1.40, P 0.0062), HSV (OR 1.11, 95% CI 1.03-1.20, P 0.0040), and VZV (OR 1.28, 95% CI 1.195-1.38, P < 0.0001) infections compared to those not on biologics. The risk of Streptococcus pneumoniae pneumonia, Actinomycosis, Nocardiosis, Cryptococcosis, Aspergillosis, Pneumocystis, influenza, and HPV was not significantly different between the two cohorts.
- Communicating Needs and Features of IBD Experiences (CONFIDE) Survey: Burden and Impact of Bowel Urgency Is Similar in Patients With Moderate-to-Severe Crohn (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_1151;
Of these, 58% US and 63% EU5 patients were receiving advanced therapies at the time of survey completion (Table). BU was among the top three most common symptoms currently (past month) experienced by US (42%) and EU5 (38%) patients with CD, similar to the findings in patients with UC (Figure).
- Biologic and Small Molecule Therapies Are Not Associated with Increased Major Adverse Cardiovascular Events (MACE) in IBD: A Propensity Matched Cohort Study (West Ballroom B) - Jul 29, 2023 - Abstract #ACG2023ACG_198;
IBD patients receiving an oral small molecule did not have increased risk of CAD (OR 1.05, 95% CI 0.82-1.33, p= 0.7148), MI (OR 1.04, 95% CI 0.60-1.78, p= 0.8903), stroke (OR 0.87, 95% CI 0.57-1.33, p= 0.5148), or VTE (OR 1.07, 95% CI 0.83-1.39, p= 0.5957) compared to patients not treated with small molecule therapy. There was a nonsignificant lower risk of stroke in IBD patients taking oral small molecules.
- | NN1213 / Novo Nordisk, Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open, Trial completion date: Lipids, Inflammation, and CV Risk in RA (clinicaltrials.gov) - Jul 27, 2023
P=N/A, N=76, Recruiting, Sponsor: Brigham and Women's Hospital
There was a nonsignificant lower risk of stroke in IBD patients taking oral small molecules. Active, not recruiting --> Recruiting | Trial completion date: Feb 2023 --> Jul 2024